Effect of antibiotic use on outcomes in patients with Hodgkin lymphoma treated with immune checkpoint inhibitors

Leuk Lymphoma. 2021 Jan;62(1):247-251. doi: 10.1080/10428194.2020.1827250. Epub 2020 Oct 6.

Authors

Steven R Hwang¹, Alexandra Higgins², Natalia E Castillo Almeida³, Betsy LaPlant⁴, Matthew J Maurer⁴, Stephen M Ansell², Thomas E Witzig², Gita Thanarajasingam², N Nora Bennani²

Affiliations

¹ Department of Medicine, Mayo Clinic, Rochester, MN, USA.
² Division of Hematology, Mayo Clinic, Rochester, MN, USA.
³ Division of Infectious Diseases, Mayo Clinic, Rochester, MN, USA.
⁴ Department of Biostatistics, Mayo Clinic, Rochester, MN, USA.

PMID: 33021136
DOI: 10.1080/10428194.2020.1827250

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Anti-Bacterial Agents / therapeutic use
Hodgkin Disease* / drug therapy
Humans
Immune Checkpoint Inhibitors
Lymphoma, Non-Hodgkin* / drug therapy
Programmed Cell Death 1 Receptor

Substances

Anti-Bacterial Agents
Immune Checkpoint Inhibitors
Programmed Cell Death 1 Receptor